Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-M Nogaret

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancerM J Piccart, A Di Leo, M Beauduin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Genomics Data|October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsB Haibe-Kains, C Desmedt, A Di Leo, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancerM J Piccart, A Di Leo, M Beauduin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Genomics Data|October 21, 2015
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsB Haibe-Kains, C Desmedt, A Di Leo, et al.
Pageof 5